Dr Fox collaborates internationally within the fields of HIV and SARS-CoV-2 infection.
Projects

CHAPS
The Combined HIV Adolescent Prevention Study (CHAPS) is a collaborative African / European HIV prevention study running in South Africa, Uganda and Zimbabwe from 2018 to 2021. The overall aims of the project are to investigate the acceptability and feasibility of implementing daily and on-demand PrEP (pre-exposure prophylaxis) among adolescents in South Africa, Uganda and Zimbabwe and to determine an on-demand PrEP dosing schedule for insertive sex. The study is divided into 3 separate phases; phase 1 is a Social Science study with the aim of identifying barriers to medication adherence, phase 2 is the clinical trial which involves giving men TDF-FTC or TAF-FTC as oral PrEP before Voluntary Male Medical Circumcision and evaluating protection through ex vivo challenge while phase 3 will investigate the efficacy of postexposure administration of the drugs.

COVAB: COVID-19 antibody repertoires in infection and vaccination
COVAB is a collaboration between the UK, South African, Sweden and Uganda to explore SARS-CoV-2 infection in terms of antibody development, mechanisms of transmission and ways to engage the public in vaccine delivery. The programme builds on capacity development from the EDCTP-CHAPS HIV prevention programme led by Dr Fox.

COVAB-B
COVAB- B is a collaboration between the UK and Switzerland to explore SARS-CoV-2 antibody repertoires in infection and following vaccination . The programme builds on capacity development from the EDCTP- SARS-CoV-2- COVAB programme led by Dr Fox.
CHERUB
CHERUB is one of the first cooperatives of UK Biomedical Research Centres to explore one of the most exciting new fields of biomedical research – HIV Cure. Internationally-recognised researchers from five Biomedical Research Centers are working together to provide a unique experimental medicine approach to new HIV therapeutic strategies. CHERUB will be the UK’s flagship in this field, bringing together, amongst others, clinicians, virologists, immunologists, molecular biologists and mathematical modellers under the umbrella of the National Institute of Health Research.

MOBILE MEN
Assessing implementation effectiveness of LA-CAB and oral FTC-TDF (daily and coitally dependent) on retention in care, coital coverage, and PrEP choice in men who are mobile for work.
Publications
News
King's study provides vital information to guide COVID-19 vaccine development
The researchers examined antibodies from people who had recovered from COVID-19 in multiple countries.

Projects

CHAPS
The Combined HIV Adolescent Prevention Study (CHAPS) is a collaborative African / European HIV prevention study running in South Africa, Uganda and Zimbabwe from 2018 to 2021. The overall aims of the project are to investigate the acceptability and feasibility of implementing daily and on-demand PrEP (pre-exposure prophylaxis) among adolescents in South Africa, Uganda and Zimbabwe and to determine an on-demand PrEP dosing schedule for insertive sex. The study is divided into 3 separate phases; phase 1 is a Social Science study with the aim of identifying barriers to medication adherence, phase 2 is the clinical trial which involves giving men TDF-FTC or TAF-FTC as oral PrEP before Voluntary Male Medical Circumcision and evaluating protection through ex vivo challenge while phase 3 will investigate the efficacy of postexposure administration of the drugs.

COVAB: COVID-19 antibody repertoires in infection and vaccination
COVAB is a collaboration between the UK, South African, Sweden and Uganda to explore SARS-CoV-2 infection in terms of antibody development, mechanisms of transmission and ways to engage the public in vaccine delivery. The programme builds on capacity development from the EDCTP-CHAPS HIV prevention programme led by Dr Fox.

COVAB-B
COVAB- B is a collaboration between the UK and Switzerland to explore SARS-CoV-2 antibody repertoires in infection and following vaccination . The programme builds on capacity development from the EDCTP- SARS-CoV-2- COVAB programme led by Dr Fox.
CHERUB
CHERUB is one of the first cooperatives of UK Biomedical Research Centres to explore one of the most exciting new fields of biomedical research – HIV Cure. Internationally-recognised researchers from five Biomedical Research Centers are working together to provide a unique experimental medicine approach to new HIV therapeutic strategies. CHERUB will be the UK’s flagship in this field, bringing together, amongst others, clinicians, virologists, immunologists, molecular biologists and mathematical modellers under the umbrella of the National Institute of Health Research.

MOBILE MEN
Assessing implementation effectiveness of LA-CAB and oral FTC-TDF (daily and coitally dependent) on retention in care, coital coverage, and PrEP choice in men who are mobile for work.
Publications
News
King's study provides vital information to guide COVID-19 vaccine development
The researchers examined antibodies from people who had recovered from COVID-19 in multiple countries.

Our Partners
EDCTP
EU
Imperial College of Science Technology and Medicine, United Kingdom
London School of Hygiene and Tropical Medicine (LSHTM), United Kingdom
University of Liverpool
Karolinska Institute, Sweden
Uganda Virus Research Institute (UVRI), Uganda
Desmond Tutu HIV Foundation
University of Zimbabwe College of Health Sciences – Clinical Trials Research Centre
University of Cape Town
Perinatal HIV Research Unit (PHRU), South Africa
Perinatal HIV Research Unit
WITS Health Consortium

European Union

Imperial College of Science, Technology and Medicine

Desmond Tutu Health Foundation

University of Cape Town

University of Zimbabwe College of Health Sciences Clinical Trials Research Centre

The Perinatal HIV Research Unit

Wits Health Consortium